



STAFF REPORT

Cardiovascular Drugs: *Global Markets to 2022*

April 2018

BCC Research Staff

Report Code: PHM191A

Table of Contents

Chapter 1: Introduction	1
Study Goals and Objectives.....	1
Reasons for Doing This Study.....	1
Scope of Report.....	1
Information Sources.....	2
Methodology.....	2
Geographic Breakdown.....	3
Analyst’s Credentials.....	7
Related BCC Research Reports.....	7
Chapter 2: Summary and Highlights	9
Chapter 3: Market Dynamics and Technology Background	15
Cardiovascular Drugs Market Definition and Overview	15
Epidemiology of Cardiovascular Diseases	16
Blockbuster Drugs	18
Market Drivers	18
Emergence of Effective Therapies for Hypertension and Hyperlipidemia	18
Increase in Aging Population	19
Government Regulations Improving Prescription Drug Assistance for the Elderly	21
Prevalence of Comorbidities Such as Diabetes and Obesity	22
Market Restraints	25
Lack of Incentives to Promote Cardiovascular Drug Development.....	25
Pricing Pressure Enforced on Manufacturers.....	26
High Cost Associated with New Drug Development and Clinical Trials	27
Patent Expiration of Blockbuster Drugs Leading to Wide Adoption of Generics.....	28
Market Opportunities	31
Focus on Prevention of Cardiovascular Disease.....	31
Emergence of Combination Therapy.....	32
Chapter 4: Pipeline Analysis	35
Research and Development Overview.....	35
Current Scenario of Cardiovascular Investments for Research and Development.....	35
Novel Drug Development/Approval.....	38
Promising Pipeline Molecules/Drugs in Development.....	43
Chapter 5: Regulatory Scenario	48
Introduction	48
Regional Regulatory Landscape	49
North America	49
Europe	52
Asia-Pacific.....	53
Cardiovascular Drugs Approved.....	57
Chapter 6: Cardiovascular Drug Delivery Systems	59
Introduction	59
Iontophoresis	60
Nanoparticle-Mediated Drug Delivery	60

Pericardiocentesis	61
Intracoronary Drug Delivery	61
Gene Therapy	61
Future Perspectives	62
Chapter 7: Market Breakdown by Disease Areas	64
Disease Type	65
Hypertension	66
Hyperlipidemia	69
Thrombosis	71
Cardiac Failure Therapy	74
Stroke	75
Arrhythmias	77
Myocardial Infarction	78
Heart Failure	79
Acute Coronary Syndrome	80
Other Cardiovascular Diseases	82
Pulmonary Hypertension	83
Peripheral Artery Diseases	84
Inflammatory Heart Disease	85
Other Diseases	85
Chapter 8: Market Breakdown by Drug Class	87
Introduction	87
Alpha-Blockers	87
Anti-Thrombotic (Anti-Coagulants and Anti-Platelets)	89
Lipid Lowering Agents	91
Anti-Hypertensives	93
Anti-Arrhythmic Drugs	97
Others	99
Chapter 9: Market Breakdown by Region	101
North America	101
United States	102
Canada	105
Mexico	105
Europe	109
Germany	110
United Kingdom	110
France	112
Italy	113
Spain	114
Rest of Europe	115
Asia-Pacific	118
China	121
Japan	122
South Korea	122
Rest of Asia Pacific	122
Middle East and Africa	126
South America	129
Chapter 10: Competitive Landscape and Key Developments	132

Major Players and Market Structure Analysis	132
Key Developments.....	133
Mergers and Acquisitions.....	135
New Product Launch.....	136
Agreement, Collaboration and Partnerships	138
Chapter 11: Company Profiles	141
Appendix: Acronyms	198
Acronyms	198
About BCC Research.....	200
About BCC Research.....	201
BCC Membership	201
BCC Custom Research	201

List of Tables

Summary Table A: Global Market for Cardiovascular Drugs, by Disease Area, Through 2022 (\$ Millions) .	9
Summary Table B: Global Market for Cardiovascular Drugs, by Drug Class, Through 2022 (\$ Millions)....	10
Summary Table C: Global Market for Cardiovascular Drugs, by Region, Through 2022 (\$ Millions)	11
Table 1 Prevalence of High Blood Pressure, Age 18+, 2015 (%)	17
Table 2 List of Blockbuster Drugs, Manufacturer, 2014-2016 (\$ Millions)	18
Table 3 Life Expectancy at Birth, both Sexes Combined, by Region (1990-2030)	20
Table 4 Prevalence Rates for Adult Obesity, by Country, 2016 (%).....	24
Table 5 Prevalence Rates of Australia Obesity for Male and Female, 1995-2015 (%).....	24
Table 6 Cardiovascular Drugs Affected by the New Drug Price Control, Brand Name, Generic Name, Manufacturer	27
Table 7 Cardiovascular Drugs Going Off-Patent, 2016-2021	29
Table 8 Giapreza Snapshot.....	39
Table 9 Uptravi Snapshot	39
Table 10 Invokana Snapshot	40
Table 11 Praluent Development Timeline	41
Table 12 Omecamtiv Mecarbil Developmental Pipeline.....	42
Table 13 AstraZeneca Plc. Cardiovascular Pipeline.....	43
Table 14 Amgen Inc. Cardiovascular Pipeline	44
Table 15 Pfizer Inc. Cardiovascular Pipeline	44
Table 16 Sanofi Cardiovascular Pipeline	44
Table 17 Novartis AG Cardiovascular Pipeline	45
Table 18 Merck and Co. Inc. Cardiovascular Pipeline	45
Table 19 Daiichi Sankyo Company, Ltd. Cardiovascular Pipeline.....	45
Table 20 Bristol-Myers Squibb Company Cardiovascular Pipeline	46
Table 21 Gilead Sciences Inc. Cardiovascular Pipeline.....	46
Table 22 Indicative List of Cardiovascular Drugs Approved by U.S. FDA and Health Canada (Brand Name, Manufacturer, Indication, Approval Date, and Approving Agency), 2015-2017	51
Table 23 Indicative List of Cardiovascular Drugs Approved by EMA (Brand Name, Manufacturer, Indication, and Approval Date), 2011-2016.....	52
Table 24 Cardiovascular Drugs Approved by PMDA (Brand Name, Manufacturer, Indication, and Approval Date), 2016-2017.....	55
Table 25 Indicative List of Cardiovascular Drugs Approved, U.S. FDA, EMA and DCGI (Generic Name, Indication, Approval Year), 2006-2011	56
Table 26 Cardiovascular Drugs Approved (Brand Name, Generic Name, Approval Year, Manufacturer, and Indication), 2011-2016.....	57
Table 27 Global Cardiovascular Drugs Market, by Disease Area, Through 2022 (\$ Millions).....	65
Table 28 Classification of Hypertension or Blood Pressure	67
Table 29 Global Hypertension Market, by Region, Through 2022 (\$ Millions)	68
Table 30 Recommended Cholesterol Levels	70
Table 31 Global Hyperlipidemia Market, by Region, Through 2022 (\$ Millions).....	70
Table 32 Global Thrombosis Market, by Region, Through 2022 (\$ Millions)	73
Table 33 Global Cardiac Failure Therapy Market, by Region, Through 2022 (\$ Millions)	74
Table 34 New York Heart Association Classification.....	79
Table 35 American Heart Association Classification.....	80
Table 36 Global Market for Other Cardiovascular Drugs, by Region, Through 2022 (\$ Millions)	82
Table 37 Global Alpha-Blockers Market, by Region, Through 2022 (\$ Millions)	88
Table 38 Global Anti-Thrombotic Market, by Region, Through 2022 (\$ Millions).....	91

Table 39 Global Lipid Lowering Agents Market, by Region, Through 2022 (\$ Millions).....	93
Table 40 Global Anti-Hypertensives Market, by Region, Through 2022 (\$ Millions).....	94
Table 41 Global Anti-Arrhythmic Drugs Market, by Region, Through 2022 (\$ Millions).....	97
Table 42 Global Anti-Arrhythmic Drug Classification, by Vaughan Williams Classification.....	98
Table 43 Global Market for Other Cardiovascular Drugs, by Region, Through 2022 (\$ Millions)	99
Table 44 Global North American Cardiovascular Drugs Market, by Country, Through 2022 (\$ Millions)	107
Table 45 European Cardiovascular Drugs Market, by Country, Through 2022 (\$ Millions)	116
Table 46 Asia-Pacific Cardiovascular Drugs Market, by Country, Through 2022 (\$ Millions).....	124
Table 47 Global Cardiovascular Companies Ranking	132
Table 48 Patent Review, 2016-2017	133
Table 49 Repatha Snapshot	137
Table 50 Jardiance Snapshot.....	137
Table 51 Industry-wide Collaborations	139
Table 52 Amgen Net Revenue, 2015-2017 (\$ Millions)	141
Table 53 Amgen Inc., Marketed Products, 2016.....	142
Table 54 Astellas Pharma Inc. Net Revenue, 2015-2017 (\$ Millions)	145
Table 55 Astellas Pharma Inc. Marketed Products, 2017	146
Table 56 AstraZeneca PLC Net Revenue, 2014-2016 (\$ Millions)	147
Table 57 AstraZeneca PLC Marketed Products, 2016	150
Table 58 AstraZeneca Global Cardiovascular Product Sales, 2014-2016 (\$ Millions).....	151
Table 59 Boehringer Ingelheim GmbH Net Revenue, 2014-2016 (\$ Millions)	153
Table 60 Boehringer Ingelheim Marketed Products, by Indication, 2016	155
Table 61 Boehringer Ingelheim GmbH Global Cardiovascular Product Sales, 2014-2016 (\$ Millions)	155
Table 62 Bristol-Myers Squibb Company Net Revenue, 2014-2016 (\$ Millions).....	157
Table 63 Bristol-Myers Squibb Company Marketed Products, 2016.....	159
Table 64 Daiichi Sankyo Company Ltd. Net Revenue, 2015-2017 (\$ Millions)	160
Table 65 Daiichi Sankyo Company Ltd. Marketed Products, by Indication, 2016	162
Table 66 Eli Lilly and Company Net Revenue, 2014-2016 (\$ Millions).....	164
Table 67 Eli Lilly and Company Marketed Products.....	166
Table 68 Gilead Sciences Inc. Net Revenue, 2014-2016 (\$ Millions)	168
Table 69 Gilead Science Inc. Marketed Products.....	169
Table 70 GlaxoSmithKline PLC Net Revenue, 2014-2016 (\$ Millions)	171
Table 71 GlaxoSmithKline PLC Marketed Products	172
Table 72 Hikma Pharmaceuticals PLC Net Revenue, 2014-2016 (\$ Millions)	173
Table 73 Hikma Pharmaceuticals PLC Marketed Products	176
Table 74 Johnson & Johnson Inc. Net Revenue, 2014-2016 (\$ Millions).....	177
Table 75 Johnson & Johnson Inc. Marketed Products, 2016.....	179
Table 76 Johnson & Johnson Inc. Marketed Products, by Indication, 2016	180
Table 77 Merck & Co. Inc. Net Revenue, 2014-2016 (\$ Millions).....	181
Table 78 Merck & Co. Inc. Marketed Products	183
Table 79 Novartis AG Net Revenue, 2014-2016 (\$ Millions)	184
Table 80 Novartis AG Marketed Products by Indication, 2016.....	186
Table 81 Pfizer Inc. Net Revenue, 2014-2016 (\$ Millions).....	188
Table 82 Pfizer Inc. Marketed Products, by Indication, 2016	189
Table 83 Sanofi Net Revenue, 2014-2016 (\$ Millions).....	190
Table 84 Sanofi Marketed Products, by Indication, 2016 (\$ Millions).....	193
Table 85 United Therapeutics Corp. Net Revenue, 2014-2016 (\$ Millions)	195
Table 86 United Therapeutics Corp. Marketed Products	195
Table 87 Abbreviations Used in Cardiovascular Drug Market	198

List of Figures

Summary Figure A: Global Market for Cardiovascular Drugs, by Disease Area, 2016-2022 (\$ Millions) ...	10
Summary Figure B: Global Market for Cardiovascular Drugs, by Drug Class, 2016-2022 (\$ Millions)	11
Summary Figure C: Global Market for Cardiovascular Drugs, by Region, 2016-2022 (\$ Millions)	12
Figure 1 Noncommunicable Diseases Mortality Share, by Cause of Death, 2015 (%).....	13
Figure 2 Top 10 Leading Causes of Death in the World, 2015 (Millions).....	16
Figure 3 Global Population Projection, Aged 60 and Above (Per 100,000 Persons)	20
Figure 4 Global Population Projection, Aged 80 and Above (Per 100,000 Persons)	21
Figure 5 United States Obesity, by State, 2016 (%)	23
Figure 6 U.S. Generic Drug Savings, 2005-2014 (\$ Billions).....	30
Figure 7 Likelihood of Approval from Phase I, by Disease Area (%)	36
Figure 8 The Center for Drug Evaluation and Research, by Therapeutic Area, 2017 (%)	37
Figure 9 Cardiovascular Drugs Approval Process, U.S. FDA and EMEA	49
Figure 10 Approved Indications for the Most Prevalent Cardiovascular Diseases, by the U.S. FDA and Health Canada, 1980-2014 (%)	50
Figure 11 China CFDA Drug Regulatory Approval Process.....	53
Figure 12 Japan PMDA Drug Regulatory Approval Process	54
Figure 13 Global Cardiovascular Disease Rates for Countries with Least Age-Standardized Mortality, 2015 (Per 100,000 Persons).....	64
Figure 14 Global Cardiovascular Disease Rates for Countries with Highest Age-Standardized Mortality, 2015 (Per 100,000 Persons).....	65
Figure 15 Global Cardiovascular Drugs Market, by Disease Area, 2016-2022 (\$ Millions)	66
Figure 16 Global Hypertension Market, by Region, 2016-2022 (\$ Millions)	68
Figure 17 Global Hyperlipidemia Market, by Region, 2016-2022 (\$ Millions).....	71
Figure 18 Global Thrombosis Market, by Region, 2016-2022 (\$ Millions)	73
Figure 19 Global Cardiac Failure Therapy Market, 2016-2022 (\$ Millions)	74
Figure 20 Global Cardiac Failure Therapy Market, by Region, 2016-2022 (\$ Millions)	75
Figure 21 Global Stroke Mortality, Per 100,000	76
Figure 22 Global Market for Other Cardiovascular Disease, 2016-2022 (\$ Millions)	82
Figure 23 Global Market for Other Cardiovascular Drugs, by Region, 2016-2022 (\$ Millions)	83
Figure 24 Global Alpha-Blockers Market, 2016-2022 (\$ Millions).....	88
Figure 25 Global Alpha-Blockers Market, by Region, 2016-2022 (\$ Millions)	89
Figure 26 Global Anti-Thrombotic Market, 2016-2022 (\$ Millions)	90
Figure 27 Global Anti-Thrombotic Market, by Region, 2016-2022 (\$ Millions).....	91
Figure 28 Global Lipid Lowering Agents Market, 2016-2022 (\$ Millions).....	92
Figure 29 Global Lipid Lowering Agents Market, by Region, 2016-2022 (\$ Millions).....	93
Figure 30 Global Anti-Hypertensives Market, 2016-2022 (\$ Millions)	94
Figure 31 Global Anti-Hypertensives Market, by Region, 2016-2022 (\$ Millions)	95
Figure 32 Global Anti-Arrhythmic Drugs Market, 2016-2022 (\$ Millions).....	97
Figure 33 Global Anti-Arrhythmic Drugs Market, by Region, 2016-2022 (\$ Millions).....	98
Figure 34 Global Market for Other Cardiovascular Drugs, by Region, 2016-2022 (\$ Millions)	99
Figure 35 Global Cardiovascular Deaths, by Region (Per 100,000 Persons) 2015 and 2030 (F).....	101
Figure 36 Global North American Cardiovascular Drugs Market, 2016-2022 (\$ Millions)	102
Figure 37 United States' CVD Deaths Share, 2016 (%)	103
Figure 38 United States Prevalence of Cardiovascular Disease Risk Factors, % of Adults.....	104
Figure 39 Obese (Body Mass Index >30) and Overweight (Body Mass Index >25) Population.....	106
Figure 40 Global North American Cardiovascular Drugs Market, by Country, 2016-2022 (\$ Millions)...	107

Figure 41 Global North American Cardiovascular Drugs Market, by Disease Area, 2016-2022 (\$ Millions)	108
Figure 42 Global North American Cardiovascular Drugs Market, by Drug Class, 2016-2022 (\$ Millions)	108
Figure 43 Global European Cardiovascular Drugs Market, 2016-2022 (\$ Millions)	109
Figure 44 United Kingdom Mortality in Males, 2015 (%)	111
Figure 45 United Kingdom Mortality in Females, 2015 (%)	112
Figure 46 Leading Causes of Death in Italy and Percent Change, 2005-2016	113
Figure 47 Spain Mortality in Women, 2014 (%)	114
Figure 48 Spain Mortality in Men, 2014 (%)	115
Figure 49 Leading Cause of Death in Europe, 2015 (%)	116
Figure 50 Global European Cardiovascular Drugs Market, by Country, 2016-2022 (\$ Millions)	117
Figure 51 Global European Cardiovascular Drugs Market, by Disease Area, 2016-2022 (\$ Millions)	117
Figure 52 Global European Cardiovascular Drugs Market, by Drug Class, 2016-2022 (\$ Millions)	118
Figure 53 Asia-Pacific Population Data, by Age Group, 2016 (Thousands)	119
Figure 54 Asia-Pacific Population Data, by Age Group, 2022 (Thousands)	120
Figure 55 Asia-Pacific Cardiovascular Drugs Market, 2016-2022 (\$ Millions)	121
Figure 56 Singapore Causes of Death, by Cardiovascular Disease Type, 2014-2016 (%)	123
Figure 57 Asia-Pacific Cardiovascular Drugs Market, by Country, 2016-2022 (\$ Millions)	124
Figure 58 Asia-Pacific Cardiovascular Drugs Market, by Disease Area, 2016-2022 (\$ Millions)	125
Figure 59 Asia-Pacific Cardiovascular Drugs Market, by Drug Class, 2016-2022 (\$ Millions)	125
Figure 60 Cardiovascular Mortality in Middle East and Africa Region, 2017 (%)	126
Figure 61 Global Middle East and Africa Cardiovascular Drugs Market, 2016-2022 (\$ Millions)	127
Figure 62 Global Middle East and Africa Cardiovascular Drugs Market, by Disease Area, 2016-2022 (\$ Millions)	128
Figure 63 Global Middle East and Africa Cardiovascular Drugs Market, by Drug Class, 2016-2022 (\$ Millions)	128
Figure 64 Global South American Cardiovascular Drugs Market, 2016-2022 (\$ Millions)	129
Figure 65 Global South American Cardiovascular Drugs Market, by Disease Area, 2016-2022 (\$ Millions)	130
Figure 66 Global South American Cardiovascular Drugs Market, by Drug Class, 2016-2022 (\$ Millions)	130
Figure 67 Amgen Inc. Revenue Share, by Region, 2017 (%)	142
Figure 68 Amgen Inc. R&D Expenditure, 2014-2016 (\$ Billions)	143
Figure 69 Astellas Pharma Inc. Revenue Share, by Region, 2017 (%)	145
Figure 70 Astellas Pharma Inc. R&D Expenditure, 2015-2017 (\$ Billions)	146
Figure 71 AstraZeneca PLC Revenue Share, by Region, 2016 (%)	148
Figure 72 AstraZeneca PLC Revenue Share, by Business Segment, 2016 (%)	149
Figure 73 AstraZeneca PLC R&D Expenditure, 2014-2016 (\$ Millions)	152
Figure 74 Boehringer Ingelheim GmbH Revenue Share, by Region, 2016 (%)	153
Figure 75 Boehringer Ingelheim GmbH Revenue Share, by Business Segment, 2016 (%)	154
Figure 76 Boehringer Ingelheim GmbH R&D Expenditure, 2014-2016 (\$ Millions)	156
Figure 77 Bristol-Myers Squibb Company Revenue Share, by Region, 2016 (%)	158
Figure 78 Bristol-Myers Squibb Company Revenue Share, by Business Segment, 2016 (%)	159
Figure 79 Daiichi Sankyo Company Revenue Share, by Business Segment, 2016 (%)	161
Figure 80 Daiichi Sankyo R&D Expenditure, 2014-2016 (\$ Billions)	163
Figure 81 Eli Lilly and Company Revenue Share, by Business Segment, 2016 (%)	165
Figure 82 Eli Lilly and Company Revenue Share, by Region, 2016 (%)	166
Figure 83 Gilead Sciences Inc. Revenue Share, by Business Segment, 2016 (%)	168
Figure 84 Gilead Sciences Inc. Revenue Share, by Region, 2016 (%)	169
Figure 85 GlaxoSmithKline PLC Revenue Share, by Business Segment, 2016 (%)	171
Figure 86 GlaxoSmithKline PLC Revenue Share, by Region, 2016 (%)	172
Figure 87 Hikma Pharmaceuticals PLC Revenue Share, by Business Segment, 2016 (%)	174

Figure 88 Hikma Pharmaceuticals PLC Revenue Share, by Region, 2016 (%).....	175
Figure 89 Johnson and Johnson Inc. Revenue Share, by Business Segment, 2016 (%)	178
Figure 90 Johnson and Johnson Inc. Revenue Share, by Region, 2016 (%)	179
Figure 91 Merck & Co. Inc. Revenue Share, by Business Segment, 2016 (%).....	181
Figure 92 Merck & Co. Inc. Revenue Share, by Region, 2016 (%).....	182
Figure 93 Novartis AG Revenue Share, by Region, 2016 (%)	185
Figure 94 Novartis AG Revenue Share, by Business Segment, 2016 (%)	186
Figure 95 Pfizer Inc. Revenue Share, by Region, 2016 (%).....	188
Figure 96 Pfizer Inc. Revenue Share, by Business Segment, 2016 (%).....	189
Figure 97 Sanofi Revenue Share, by Region, 2016 (%)	191
Figure 98 Sanofi Revenue Share, by Business Segment, 2016 (%)	192
Figure 99 Sanofi R&D Expenditure, 2014-2016 (\$ Millions)	194



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or email info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781-205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-668-4
April 2018